DA
GERM

DCM Advisors’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

DCM Advisors’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,100
Closed -$86K – 331
2021
Q3 		$86K Hold
2,100
– – 0.03% 256
2021
Q2 		$84K Hold
2,100
– – 0.05% 220
2021
Q1 		$75K Buy
+2,100
New +$78.7K 0.04% 218

Other funds holding GERM

LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

DCM Advisors's GERM Position: Q4 2021 in Review

DCM Advisors sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q4 2021, closing a stake of 2,100 shares — an estimated $86K sold.

DCM Advisors first reported a position in GERM in Q1 2021 and held it in 3 quarters. The position peaked at $86K in Q3 2021. 30 funds tracked by Wall St. Rank hold GERM as of Q4 2021.

  • DCM Advisors reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q4 2021 after selling out during the quarter.
  • DCM Advisors sold 2,100 Amplify Treatments, Testing and Advancements ETF shares in Q4 2021, an estimated $86K.
  • DCM Advisors first reported a position in Amplify Treatments, Testing and Advancements ETF in Q1 2021 and held it in 3 quarters.
  • DCM Advisors's Amplify Treatments, Testing and Advancements ETF position peaked at $86K in Q3 2021.
  • 30 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q4 2021.

Based on DCM Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.